Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Eledon Pharmaceuticals, Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Eledon Pharmaceuticals, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • Eledon Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2025 was $17,402,000, a 123% decline year-over-year.
  • Eledon Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2016 was $37,905,000, a 16% increase from 2015.
  • Eledon Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2015 was $45,142,000, a 94% decline from 2014.
  • Eledon Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2014 was $23,296,000, a 48% decline from 2013.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Eledon Pharmaceuticals, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $17,402,000 -$94,475,000 -123% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $11,246,000 +$33,661,000 +75% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $6,539,000 +$17,092,000 +72% 01 Jan 2025 31 Mar 2025 10-Q/A 14 Aug 2025 2025 Q1
Q3 2024 $77,073,000 +$86,979,000 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $44,907,000 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $23,631,000 01 Jan 2024 31 Mar 2024 10-Q/A 14 Aug 2025 2025 Q1
Q3 2023 $9,906,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q1 2017 $30,394,000 $3,865,000 +$7,511,000 +66% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2017 2017 Q1
Q4 2016 $37,905,000 $3,741,000 +$7,339,000 +66% 01 Oct 2016 31 Dec 2016 10-K 03 Mar 2017 2016 FY
Q3 2016 $45,244,000 $9,273,000 +$2,570,000 +22% 01 Jul 2016 30 Sep 2016 10-Q 03 Nov 2016 2016 Q3
Q2 2016 $47,814,000 $13,515,000 -$4,556,000 -51% 01 Apr 2016 30 Jun 2016 10-Q 04 Aug 2016 2016 Q2
Q1 2016 $43,258,000 $11,376,000 +$1,884,000 +14% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $45,142,000 $11,080,000 01 Oct 2015 31 Dec 2015 10-K 03 Mar 2017 2016 FY
Q3 2015 $11,843,000 -$5,453,000 -85% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $8,959,000 -$3,108,000 -53% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $13,260,000 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q3 2014 $6,390,000 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015 2015 Q3
Q2 2014 $5,851,000 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2015 2015 Q2

Eledon Pharmaceuticals, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2016 $37,905,000 +$7,237,000 +16% 01 Jan 2016 31 Dec 2016 10-K 03 Mar 2017 2016 FY
2015 $45,142,000 -$21,846,000 -94% 01 Jan 2015 31 Dec 2015 10-K 03 Mar 2017 2016 FY
2014 $23,296,000 -$7,571,000 -48% 01 Jan 2014 31 Dec 2014 10-K 03 Mar 2017 2016 FY
2013 $15,725,000 01 Jan 2013 31 Dec 2013 10-K 10 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.